NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.
Germany's Curetis has initiated a prospective clinical trial in the European Union for its Unyvero molecular testing system and P50 Pneumonia test cartridge, the company said in February.
By Ben Butkus
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Curetis today announced its Series A financing round has increased by €9.6 million ($13.3 million) bringing the total amount raised in the round to €34.1 million.
According to founder and CEO Scott Tanner, the funds will go primarily toward ramping up production of CyTOF instruments, reagent production, and the establishment of a global sales and service team.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.